COMP <GO>
KURA vs CYRX // PIOTROSKI F-SCORE QUALITY
Kura Oncology Inc. (NASDAQ) VS. CryoPort Inc. (NASDAQ) • 15-METRIC TALLY: KURA 2
— CYRX 7
▲ PIOTROSKI F-SCORE QUALITY LEADER: CYRX
LAST: $10.26 (-2.84%) • MKT CAP: $939.4M
piotroski-score
4/9
LAST: $17.29 (-5.47%) • MKT CAP: $926.4M
piotroski-score
5/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KURA VS. CYRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KURA | CYRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 47.10% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -11.50% | -23.50 | CYRX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.53% | -2.70% | -4.83 | CYRX | /fcf-yield <GO> |
| Operating Margin | -60.00% | -20.90% | -39.10 | CYRX | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 44.40% | -104.40 | CYRX | /net-margins <GO> |
| Revenue Growth (YoY) | 25.20% | 12.40% | +12.80 | KURA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 1.33 | -1.13 | CYRX | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 4/9 | 5/9 | -1.00 | CYRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.1 | 56.6 | -3.50 | CYRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 9.9x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $939.4M | $926.4M | $13.1M | KURA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KURA REV | CYRX REV | KURA GROSS % | CYRX GROSS % | KURA FCF | CYRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $67.5M | $176.2M | — | 47.1% | -$70.7M | -$25.0M |
| FY 2024 | $53.9M | $156.8M | — | 44.4% | $133.8M | -$33.6M |
| FY 2023 | $0 | $168.7M | — | — | -$124.8M | -$757.0K |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KURA // BETA —
CYRX // BETA —